Sistemic candidiasis is a serious emergent problem in Neonatal Intensive Care Unit. Recently, several studies have demonstrated that Amphotericin B(AmB) in Colloidal Dispersion (Amphocil®) is far less toxic than the conventional AmB. Objective: We studied 5 infants with sistemic candidiasis treated by Amphotericin B in Colloidal Dispersion with the purpose to assess free serum levels and renal and hepatic toxicity. Methods: The treatment consisted of the administration of Amphotericin B in Colloidal Dispersion at an initial dose of 1mg/Kg per day intravenously as a continuous infusion for 30 minutes, increasing 0,5 mg/Kg every 24 h up to 3 mg/Kg per day. Seven days after initiation of treatment, blood was taken to determine trough and peak free serum levels of AmB by High Performance Liquid Chromatography. At this time samples were taken for urea, creatinine, aspartate amino transferase(SGOT, normal values=2-20UI/L) and alanine amino transferase (SGPT, normal values=2-15UI/L). Results are showed in table. Conclusions: The serum levels of Amphotericin B in Colloidal Dispersion were similar to those verified with conventional AmB(therapeutic levels: peak = 1.0 - 1.5mcg/ml; trough = 0.5 - 1.0 mcg/ml). No impairment of renal function were detect; two infants (cases 2,4) showed slight increases in serum SGOT and SGPT.

Table 1 No caption available.
Full size table